Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmathen

- PMLiVE

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

- PMLiVE

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Monthly meeting held remotely for the first time due to COVID-19 pandemic

- PMLiVE

EMA calls for pooled EU research into COVID-19 therapies

Asks for a harmonised methodology across member states

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

- PMLiVE

NHS England will make PrEP for HIV available in April

Will be made available to patients at risk of contracting infection

EU flag

EMA to consider coronavirus’ impact on EU medicines supply

Steering group will identify EU-wide actions to mitigate medicine supply risks

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

EISAI

Eisai agrees to pull obesity drug Belviq after safety alert

Weight-loss drug linked to increased risk of cancer

- PMLiVE

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail

- PMLiVE

Givlaari, Rybelsus lead crowded CHMP recommendations

EU regulator delivered 15 positive opinions and no rejections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links